Beijing Kawin Technology Share-holding Co Ltd (688687) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Kawin Technology Share-holding Co Ltd (688687) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.41 Million ≈ $3.86 Million USD) by net assets (CN¥1.83 Billion ≈ $267.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688687 net asset quality index to measure how much of total assets are equity-financed.
Beijing Kawin Technology Share-holding Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Beijing Kawin Technology Share-holding Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Beijing Kawin Technology Share-holding C (688687) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Beijing Kawin Technology Share-holding Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Kawin Technology Share-holding Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Real Brokerage Inc
NASDAQ:REAX
|
0.355x |
|
Issta Lines Ltd
TA:ISTA
|
0.034x |
|
Fujian Tendering Co. Ltd.
SHE:301136
|
N/A |
|
Plastika Kritis S.A.
AT:PLAKR
|
0.019x |
|
Lesaka Technologies Inc
NASDAQ:LSAK
|
0.144x |
|
Foresee Pharmaceuticals Co Ltd
TWO:6576
|
-0.162x |
|
LF Corp
KO:093050
|
0.051x |
|
SHANDONG BOAN BIOTECH.H 1
F:UJ9
|
N/A |
Annual Cash Flow Conversion Efficiency for Beijing Kawin Technology Share-holding Co Ltd (2009–2025)
The table below shows the annual cash flow conversion efficiency of Beijing Kawin Technology Share-holding Co Ltd from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Beijing Kawin Technology Share-holding C (688687) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.74 Billion ≈ $254.60 Million |
CN¥110.29 Million ≈ $16.14 Million |
0.063x | +14.30% |
| 2024-12-31 | CN¥1.88 Billion ≈ $275.15 Million |
CN¥104.29 Million ≈ $15.26 Million |
0.055x | -21.79% |
| 2023-12-31 | CN¥1.79 Billion ≈ $261.23 Million |
CN¥126.60 Million ≈ $18.53 Million |
0.071x | -11.02% |
| 2022-12-31 | CN¥1.68 Billion ≈ $246.10 Million |
CN¥134.05 Million ≈ $19.62 Million |
0.080x | +14.04% |
| 2021-12-31 | CN¥1.69 Billion ≈ $246.93 Million |
CN¥117.94 Million ≈ $17.26 Million |
0.070x | -54.60% |
| 2020-12-31 | CN¥853.63 Million ≈ $124.91 Million |
CN¥131.42 Million ≈ $19.23 Million |
0.154x | +15.43% |
| 2019-12-31 | CN¥771.85 Million ≈ $112.95 Million |
CN¥102.94 Million ≈ $15.06 Million |
0.133x | +44.82% |
| 2018-12-31 | CN¥654.87 Million ≈ $95.83 Million |
CN¥60.31 Million ≈ $8.83 Million |
0.092x | +297.24% |
| 2017-12-31 | CN¥612.36 Million ≈ $89.61 Million |
CN¥14.20 Million ≈ $2.08 Million |
0.023x | +55.63% |
| 2015-12-31 | CN¥545.83 Million ≈ $79.87 Million |
CN¥8.13 Million ≈ $1.19 Million |
0.015x | -92.81% |
| 2014-12-31 | CN¥239.73 Million ≈ $35.08 Million |
CN¥49.67 Million ≈ $7.27 Million |
0.207x | +172.70% |
| 2013-12-31 | CN¥220.74 Million ≈ $32.30 Million |
CN¥16.77 Million ≈ $2.45 Million |
0.076x | -56.11% |
| 2012-12-31 | CN¥163.93 Million ≈ $23.99 Million |
CN¥28.38 Million ≈ $4.15 Million |
0.173x | -34.24% |
| 2011-12-31 | CN¥122.53 Million ≈ $17.93 Million |
CN¥32.26 Million ≈ $4.72 Million |
0.263x | -2.90% |
| 2010-12-31 | CN¥92.84 Million ≈ $13.59 Million |
CN¥25.17 Million ≈ $3.68 Million |
0.271x | -39.47% |
| 2009-12-31 | CN¥38.91 Million ≈ $5.69 Million |
CN¥17.43 Million ≈ $2.55 Million |
0.448x | -- |
About Beijing Kawin Technology Share-holding Co Ltd
Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more